Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.

ABSTRACT:

Aims

Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) have relapsed or refractory (R/R) disease after first-line treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, and outcomes are poor after hematopoietic stem cell transplantation failure. CheckMate 436 (NCT02581631) was a phase 1/2 study to evaluate the efficacy and safety of nivolumab, a PD-1/PD-L1 inhibitor, plus brentuximab vedotin (BV) for the treatment of R/R non-Hodgkin lymphoma.

Materials and methods

Adult patients received nivolumab plus BV in 3-week cycles. The primary endpoint was overall response rate (ORR). Here, we report the results from the R/R DLBCL cohort (n = 42).

Results

With a median follow-up of 7.7 months, the ORR was 28.6% (n = 12), and 7.

SUBMITTER: Johnson NA 

PROVIDER: S-EPMC12773585 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature